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Summary points
• Antimicrobial use in low- and middle-income country (LMIC) food animal produc-
tion sectors is accelerating, commensurate with expanded intensive production to
meet rapidly increasing demand for animal-source nutrition.
• However, antimicrobial consumption in animal production contexts of LMICs
remains largely undocumented, limiting the ability to establish and monitor progress
toward achieving consumption targets.
• We propose the establishment of antimicrobial consumption monitoring systems in a
phased manner that will be responsive and adaptive to LMIC contexts, while directing
a path toward incremental enhancement of monitoring structures.
• This phased approach enables implementation of systems yielding standardized, glob-
ally comparable antimicrobial consumption data, which could inform policies to opti-
mize antimicrobial usage in food animal production.
• The approach should be complemented by efforts to strengthen animal production
systems, eliminate medically important antimicrobial growth promoters, and reduce
reliance upon prophylactic antimicrobial use.
Global antimicrobial consumption in terrestrial and aquatic food animal production is acceler-
ating, associated with expanded production to meet increasing demand for animal-source
nutrition [1]. In South Asia, for example, demand for poultry between 2000 and 2030 is
expected to increase by 725% [2]. Overall, growth in demand for animal-source nutrition
through 2030 is anticipated to be higher in low- and middle-income countries (LMICs) as
compared with high-income countries [2].
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Efforts to meet rising demand for animal-source nutrition in LMICs are driving a shift in
animal production from small holder, mixed crop, and livestock operations to increasingly
intensive, large-scale, and specialized commercialization [1,3]. Intensive production systems
have historically employed nontherapeutic antimicrobial use, particularly during transitionary
stages [1]. Nontherapeutic antimicrobial use includes both mass administration for prevention
and control of disease and antimicrobial growth promoter (AGP) use. AGPs are antimicrobials
administered at subtherapeutic doses, are intended to enhance growth and production effi-
ciencies, and are generally delivered in feed or water for extended duration. Although AGPs
are not authorized in many countries, LMIC regulatory structures are often insufficient to
monitor and enforce AGP bans.
Quantitative volumes of AGP usage from LMICs are not available. However, studies from
LMICs indicate substantial nontherapeutic use. In the Mekong Delta of Vietnam, 84% of poul-
try farms surveyed indicated that antimicrobials were used for prophylactic rather than thera-
peutic purposes, and nearly a third of overall usage involved antimicrobial classes on the
WHO list of highest priority, critically important antimicrobials for human medicine [4]. As a
consequence of this changing landscape of animal production, without appropriate policy to
optimize use, global antimicrobial consumption in food-producing animals, estimated at
131,109 tons in 2013, is projected to increase over 50% by 2030 to 200,235 tons [5]. In the
BRICS countries—Brazil, Russia, India, China, and South Africa—antimicrobial consumption
in food animals is projected to double [1].
The discovery and commercialization of antimicrobials stands as a defining achievement of
20th century medicine. As usage patterns drive rising rates of antimicrobial resistance (AMR)-
linked morbidity and mortality [6]—compounded by a formidable cross-sectoral economic
burden [7]—the global community faces an unprecedented challenge of preserving—and
maintaining in perpetuity—antimicrobial efficacy.
Antimicrobial usage (AMU) in humans and animals exerts selection pressure potentiating
AMR [1,5–8]; policy goals aim to reduce antimicrobial use where effective alternatives are
available. A standardized framework guiding collection of incrementally detailed, internation-
ally comparable antimicrobial consumption data from animal production could accelerate
progress toward optimizing global antimicrobial use (Box 1). Yet, no such standardized
Box 1. Benefits expected from establishing a standardized
framework for antimicrobial consumption in animal production
1. Monitor consumption trends and benchmarking for optimization of antimicrobial
consumption.
• Facilitates identification of trends and usage profiles,
• Permits establishment of time-bound consumption targets,
• Monitors progress toward achieving targets,
• Guides policy and targeted interventions optimizing antimicrobial use.
2. Comparison of antimicrobial consumption data across countries, species, farms,
and with human consumption.
• Comparison of consumption data ultimately disaggregated by species and com-
parable across human and animal sectors,
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002521 March 1, 2018 2 / 9
antimicrobial usage; API, active pharmaceutical
ingredient; ATCvet, Anatomical Therapeutic
Chemical classification for veterinary medical
products; BRICS, Brazil, Russia, India, China, and
South Africa; DCDvet, defined course dose in
animals; DDD, defined daily dose; DDDvet, defined
daily dose in animals; ESVAC, European
Surveillance of Veterinary Antimicrobial
Consumption; FAO, Food and Agriculture
Organization of the United Nations; IACG,
Interagency Coordination Group on Antimicrobial
Resistance; JEE, Joint External Evaluation; LMIC,
low- and middle-income country; OIE, World
Organization for Animal Health; PCU, population
correction unit; Thai SAC, Thailand’s Surveillance
for Antimicrobial Consumption.
Provenance: Not commissioned; externally peer
reviewed
framework relevant to LMIC animal production contexts exists [9,10], challenging the charac-
terization of usage and limiting government policies aimed at optimizing and monitoring
AMU in animal production sectors.
The challenge of establishing surveillance of antimicrobial
consumption in animal production
The measurement of AMU in human health and animal health and production settings is a
central goal of the Global Action Plan on Antimicrobial Resistance [11] and the complemen-
tary plans and strategies developed by the Food and Agriculture Organization of the United
Nations (FAO) and World Organization for Animal Health (OIE) [12,13].
The ecosystem in which veterinary antimicrobials are produced, distributed, and utilized in
LMICs is complex and variable. A majority of LMICs currently lack structures capable of
quantifying consumption at sufficient resolution to provide usage data by antimicrobial class,
animal species, production context, purpose of usage, and route of administration, which are
necessary to facilitate effective interventions to optimize use [14]. Of the 74 LMIC OIE mem-
ber states, 54 (73%) reported AMU to the OIE in 2015, while 20 (27%) provided no reporting
at all. Of the 54 member states reporting, 30 (55.6%) were able to provide some quantitative
usage data but were largely unable to report that data disaggregated by the aforementioned
parameters [14].
Patterns of antimicrobial use differ widely across animal production value chains, as evi-
denced by macrolide, fluoroquinolone, and tetracycline residue detection in animal products
marketed for human consumption [15], but species-level consumption data from LMICs are
largely unavailable [16]. Reports are inconsistent, challenging international comparison due to
lack of measurement standardization. A more complete picture of consumption variability is
imperative in identifying targeted action toward optimizing usage.
Despite calls for establishing usage thresholds and targets [5,7,17], in the absence of an
implementable, globally standardized methodology for quantifying consumption, progress
toward setting, measuring, and achieving targeted usage benchmarks will remain limited.
Other challenges frequently shared by LMICs (Box 2) are equally important in realizing
progress toward optimizing usage, and addressing them will require a foundational evidence
base on consumption.
Standardizing measurement methodologies in the context of
LMICs
Multiple methodologies for quantifying usage have been variously employed, hindering data
comparability across countries and production sectors. The OIE terrestrial animal health code,
• Antimicrobial consumption data become globally comparable,
• Contributes to international benchmarking,
• Creates a globally standardized monitoring architecture, upon which a future
international agreement capping consumption could be developed.
3. Builds a platform for studying the association between antimicrobial consumption
and AMR surveillance data.
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the guiding framework for its 180 member nations, outlines the minimum standard as mea-
suring gross usage by weight of active ingredient per year [18].
Through the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)
activity, European Union member states voluntarily report antimicrobial use by food animal–
producing species [19]. The ESVAC guidance aims to harmonize antimicrobial consumption
data and enable comparison with AMR surveillance data.
Antimicrobial consumption in food animals can be crudely estimated by quantifying the
total weight of the active ingredient adjusted for biomass eligible for treatment, usually
expressed as mg/kg population correction unit (PCU), where PCU is defined as total live and
slaughtered animal weight per year in a prescribed geographic area. While this measurement
of total volume of active ingredient per biomass considers neither the concentration of admin-
istered product nor its pharmacokinetics in individual species, it is a readily calculated estimate
of usage. ESVAC guidelines use the mg/PCU methodology and introduce both defined daily
dose in animals (DDDvet) and defined course dose in animals (DCDvet) [20], serving two func-
tions: comparability across a range of species, usage, pharmaceutical formulations, and dosing
regimens and aligning AMU methodologies in animals to those in humans, namely the
defined daily dose (DDD) per 1,000 population per day endorsed as a global standard by
WHO [21]. However, DDDvet and DCDvet—proprietary ESVAC reporting nomenclature sim-
ilar to animal defined daily dose (ADDD) and animal defined course dose (ADCD), respec-
tively—are not suited to contexts in which measurement must also capture continuous-use,
subtherapeutic dosing, as in LMICs where policies governing AGP use vary significantly.
A phased capacity framework: Toward a global architecture for
quantifying AMU in animal production
Accurate accounting of antimicrobial consumption in food-producing animals of LMICs
must capture both therapeutic and nontherapeutic use, including AGPs and mass administra-
tion of antimicrobials delivered in medicated, premixed feed. Antimicrobial consumption
monitoring is particularly important in aquaculture, in which mass administration of antimi-
crobials in medicated feed for disease prevention and control is a standard practice [22].
Box 2. Challenges experienced by LMICs in optimizing antimicrobial
consumption in animal production sectors
• Low rates of AMR awareness and risk perception among farmers and veterinarians
[15],
• Inconsistent policies governing antimicrobial use in animal production,
• Absent AMU regulation and enforcement structures enabling wide accessibility to
critically important antimicrobials without prescription,
• Where a legal veterinarian–client–patient relationship exists governing prescription
use of antimicrobials in animals, the link between prescription and sales presents a
sales volume profit incentive, and
• Lack of systematic post-market quality surveillance that would enable recall of sub-
standard and counterfeit veterinary antimicrobial products impacting therapeutic
efficacy.
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We propose a standardized, internationally-endorsed, phased approach that accounts for
the context and currently available structures for collecting AMU data from food-producing
animals—both terrestrial and aquatic species—in LMICs. The foundation is built upon the
annual measurement of total sales of antimicrobials by class in mg/PCU, which can be derived
from the total sales by class for member states reporting to the OIE divided by animal biomass
data. Consistency in deriving the numerator—active pharmaceutical ingredient (API)—across
multiple formulations of veterinary antimicrobials necessitates that products be managed
through a standardized classification scheme, such as the Anatomical Therapeutic Chemical
(ATCvet) system established for veterinary medical products [23]. Similarly, the animal bio-
mass PCU denominator must employ a clearly and consistently applied calculation, using
standardized production cycle and weight parameters [19] and accounting for animals locally
produced, minus import and plus export of animals across borders. Leveraging existing, aggre-
gate antimicrobial importation data; API domestic manufacturing and export data; antimicro-
bial sales data; and all-species animal biomass estimates publicly available [24] permit the
rapid adoption of this foundational measurement scheme and bypasses substantial challenges
in some LMICs of bottom-up quantification at the farm level, where legal requirements for
identifying antimicrobials premixed into animal feed do not presently exist.
As countries establish refined data collection structures (Box 3), measurements could corre-
spondingly evolve in subsequent phases to encompass more detailed parameters, including
disaggregation by species and production type, and enhanced methodologies, such as number
of animal defined daily doses (Table 1). Advanced phases could also involve collection sources
more proximal to the site of usage—ultimately, at the individual animal or herd/flock/pond
level—providing increasingly rich data sources directing optimal usage profiles and enabling
usage audits and gap analysis for continued professional education. Achieving this detail
requires both verifiable on-farm record keeping and longitudinal or serial, cross-sectional sur-
veys capturing usage. Linkages with legislation and enforcement of appropriate incentive–pen-
alty structures and establishment of an independent audit system will enhance compliance.
Technical assistance could be housed within existing or newly established coordinating
bodies and should prioritize intraregional LMIC exchanges and solutions relevant to unique
Box 3. Application of the phased antimicrobial consumption
monitoring approach in Thailand
In 2015, Thailand’s International Health Policy Program and One Health partners estab-
lished a human and animal national Surveillance for Antimicrobial Consumption (Thai
SAC) system [25,26]. Thailand’s 1967 Drug Act mandates pharmaceutical importers and
producers to submit an annual report on total volume of importation and manufacture
of all medicines, including antimicrobials, to the Thai Food and Drug Administration.
This total national antimicrobial sales data forms the foundation of Thai SAC, although
the current reporting format does not require disaggregation by animal species. A 4-year
(2014–2017) retrospective consumption study, with expected completion by mid-2018,
will report mg active ingredient per PCU totaled across all animal species. Illustrating
the application of an incremental, phased approach, in 2017, electronic information sys-
tems are being developed to facilitate e-reporting total sales of antimicrobial classes by
animal species [27].
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regional capacities and contexts. An intergovernmental panel on AMR has been suggested
[28], similar to structures designed to catalyze global action on climate change. The United
Nations ad hoc Interagency Coordination Group on Antimicrobial Resistance (IACG), formed
at the 71st UN General Assembly in 2016, comprises agencies including the WHO-FAO-OIE
tripartite, which can jointly coordinate technical and operational assistance between member
countries [29].
The path forward in optimizing AMU in food animal production
sectors
Documenting usage—particularly for WHO-classified highest priority critically important
antimicrobials—permits trends monitoring and identification of animal production sectors in
which targeted interventions hold promise of arresting drivers of resistance. Conceivably, a
reversion to susceptibility is achievable, as noted in Salmonella enterica Serovar Heidelberg fol-
lowing elimination of third-generation cephalosporins from poultry hatcheries in Quebec,
Canada [30].
Establishing antimicrobial consumption monitoring systems in animal production sectors
should be a central, near-term goal of multisectoral national AMR action plans aligned with
the WHO Global Action Plan and the focus of advocacy and support from the UN FAO, OIE,
and WHO tripartite. Embedding this approach within national AMR action plans promotes
monitoring capacities endorsed across ministries, including those vested with budget author-
ity, and costed, resourced, and prioritized for implementation.
Table 1. Phased capacity approach to establishing surveillance for antimicrobial consumption in food animal production context of LMICs.
Parameter Phase One Phase Two Phase Three Phase Four Phase Five
Methodology mg/PCU mg/PCU mg/PCU mg/PCU and ADDD mg/PCU, ADDD, and ADCD
Unit of
Measurement
mg/PCU mg/PCU disaggregated
by species
mg/PCU disaggregated by
species and production type
mg/PCU and number of
ADDDs
mg/PCU and number of
ADDDs and ADCDs
Data
Requirements
- Total annual API
sales (imported and
manufactured minus
exported) by class
- Total annual animal
biomass (locally
produced minus
imported, plus
exported)
- Total annual API sales
(imported and
manufactured minus
exported) by class and
animal species
- Total annual animal
biomass by species
(locally produced minus
imported, plus exported)
- Total annual API sales
(imported and
manufactured minus
exported) by class, animal
species, and production
type
- Total annual animal
biomass by species and
production type (locally
produced minus imported,
plus exported)
Phase three data plus:
- On-farm consumption data by
species/type (mg/kg/day), route,
and intended use, derived from
product formulation,
concentration, and unit size
- On-farm production figures
Phase four data plus:
- On-farm consumption data by
species/type (mg/kg/course),
route, and intended use, derived
from product formulation,
concentration, and unit
- On-farm production figures
Data Source - National registry of
API sales
- Animal production
census data
- National registry of API
sales
- Distributor and end-
user checks
- Animal production
census data
- National registry of API
sales
- Distributor and end-user
checks
- Animal production census
data
Phase three sources plus:
- On-farm usage reporting and
production records, as collected
from producers, veterinarians,
pharmacies, feed mills
Phase three sources plus:
- On-farm usage reporting and
production records, as collected
from producers, veterinarians,
pharmacies, feed mills
Reporting
Frequency
Annual Annual Annual Annual Annual
PCU is defined as total live and slaughtered animal biomass in kg for a prescribed geographic area.
Number of ADDDs is expressed in number/1,000 animals/year, where a standardized ADDD is the mean of all observed doses of antimicrobial across indications for
a given species in mg/kg per day; presently, no global standardized ADDD exists and would need to be established for priority food-producing animal species.
Number of ADCDs is expressed in number/1,000 animals/year, where a standardized ADCD is in mg/kg/treatment course.
Abbreviations: ADCD, animal defined course dose; ADDD, animal defined daily dose; API, active pharmaceutical ingredient; LMIC, low- and middle-income country;
mg, milligram; PCU, population correction unit.
https://doi.org/10.1371/journal.pmed.1002521.t001
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In parallel, the WHO Joint External Evaluation (JEE) tool, which explicitly considers AMR
and is increasingly being utilized by countries as an independent assessment of International
Health Regulations (2005) capacity requirements [31], could develop an indicator evaluating
AMU monitoring capacities. The JEE’s 1 (no capacity) to 5 (sustainable capacity) scoring
structure is well matched to the phased, incrementally enhanced monitoring pathway pre-
sented here (Table 1), and incorporating a distinct indicator would ensure dedicated consider-
ation of usage monitoring in human and animal sectors.
Antimicrobial consumption monitoring systems alone, however, will be insufficient to real-
ize progress in directing prudent AMU in food-producing animals. Concurrently, support for
strengthened farm and market chain biosecurity, enhanced livestock vaccination coverage,
and improved uptake of good animal husbandry and nutrition practices will be necessary in
achieving optimized usage, particularly in transitioning food animal production contexts of
LMICs. New production facilities in LMICs should be designed to achieve high standards of
husbandry and biosecurity, enabling more rapid phaseout of AGPs. Eliminating AGPs can be
achieved at negligible cost to productivity, particularly in the context of such strengthened pro-
duction systems [32].
The framework presented here should provide LMIC policy makers with high-quality anti-
microbial consumption data that can be used to establish usage targets, while building incre-
mentally enhanced monitoring capacities. The analyses derived from this approach could steer
targeted policies optimizing antimicrobial consumption and scale back selective pressures cur-
rently driving AMR in animal production, with benefits expected to extend broadly across ani-
mal and human health.
Disclaimer
The authors’ views expressed in this publication do not necessarily reflect the views of the
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